Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Clearmind Medicine C.CMND

Alternate Symbol(s):  CMNDF

Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (CSE:CMND)

Fundamentals Snapshot (CSE:CMND)

Opinion & Analysis (CSE:CMND)

No current opinion is available.

Bullboard Posts (CSE:CMND)

FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent

 
Karylle - July 15, 2022

FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance

<< View Post To Watch Video >> FSD Pharma ready to proceed with Phase 2 clinical trial of FSD-201 as soon as it gets...
Karylle - June 3, 2022

FSD Pharma Files Investigational New Drug Application “IND”

Karylle - June 2, 2022

Clearmind Medicine and SciSparc find positive results

The two companies work together and yeild positive results for the Psychedelic Combination Treatment.
BMcCutcheon - May 25, 2022

Clearmind announces upcoming pre-IND meeting with the FDA

https://themarketherald.ca/clearmind-announces-pre-ind-meeting-date-with-fda-2022-05-13/
TrevorAbes - May 13, 2022

FSD Pharma Closes CAD$16.4 Million Sale of Non-Core Assets

 
Karylle - May 11, 2022